{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 19,
  "pageCount": 41,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a Gantt-style timeline to illustrate clinical trial phases and patient cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/19",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.88,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Clinical trial study design diagram showing Screening, Part A, Part B, and Part C with study arms L, M, H, H1, and H2.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11964c7a-52d4-40d7-975d-6cd19aa97a61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.65,
        "y": 0.8
      },
      "kind": "legend",
      "text": "Re-vaccination at Month 6 and 12 with the highest dose (homologous viral challenge)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03716c98-6262-4db2-af8b-06e02b7fe89f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.22,
        "y": 0.08
      },
      "kind": "legend",
      "text": "Safety including viremia on Days 0/3/7/14 post-vaccination",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3530d6b1-df21-49e9-9ef9-44c3136363a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.06,
        "y": 0.16
      },
      "kind": "list",
      "text": "Observer-blinded, randomized, multicenter, dose escalation study\nStudy Population: 120 healthy volunteers aged 18 to 45 years\nDosage: 3.2x10^3 TCID50 (0.1ml), 3.2x10^4 TCID50 (1ml), 3.2x10^5 TCID50 (1ml)\nImmunization route: intramuscular",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6174e9d-76af-43d9-896a-fff8f680ac5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1 Trial Led to Direct Progression into Phase 3",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9c416cf-879c-48e7-89b7-a1bf7fa735d2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "9d8e7041-cb25-4209-aded-5b48c628c0fa",
      "evidence": "The slide uses a horizontal timeline to represent phases and study arms.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}